In a most recent meta‐analysis by Wang et al, TET2 mutations predicted inferior overall survival as well as event‐free survival for patients with AML, and specifically in patients under 65 years of age (the authors noted that a data deficiency prevented an analysis of patients over 65 years of age) and those cytogenetically normal and intermediate‐risk AML.162. The gene discussed is TET2; the disease is acute myeloid leukemia.